Author/Authors :
Chen, Yueming Dept. of Laboratory Medicine - Hangzhou First People’s Hospital, Hangzhou, China , Yu, Daojun Dept. of Laboratory Medicine - Hangzhou First People’s Hospital, Hangzhou, China , Zhang, Weiying Dept. of Laboratory Medicine - Hangzhou First People’s Hospital, Hangzhou, China , Qiu, Chunning Dept. of Laboratory Medicine - Hangzhou First People’s Hospital, Hangzhou, China , Xiang, Guoqian Dept. of Laboratory Medicine - Hangzhou First People’s Hospital, Hangzhou, China , Dai, Weijian Dept. of Laboratory Medicine - Hangzhou First People’s Hospital, Hangzhou, China , Wu, Shenghai Dept. of Laboratory Medicine - Hangzhou First People’s Hospital, Hangzhou, China , Wang, Xianjun Dept. of Laboratory Medicine - Hangzhou First People’s Hospital, Hangzhou, China
Abstract :
Background: To glean insights into the relationship among hepatitis B virus (HBV) genotype/subgenotypes,
A1762T/G1764A mutations and advanced liver disease such as liver cirrhosis (LC) and hepatocellular carcinoma
(HCC) in Southeast China.
Methods: A case-control study was performed, consisting of chronic hepatitis B (CHB) patients (n=160), LC patients
(n=150), and HCC patients (n=156). Fluorescence quantitative polymerase chain reaction (FQ-PCR) was used to detect
A1762T/G1764A mutations. HBV genotypes/subgenotypes were determined by multiplex PCR. All patients’
clinical data was systematically collected from the hospital records.
Results: Our study revealed HBV genotypes C (63.95%) and B (33.69%) were predominant in chronically infected
patients, subgenotype B2, C2 and C1 were the major subgenotypes. Both subgenotype C2 infection and
A1762T/G1764A mutations were associated with LC and HCC with cirrhosis, subgenotype C2 (OR=2.033,
95%CI=1.246-3.323, P=0.003 for LC vs CHB; OR=3.247, 95%CI=1.742-6.096, P=0.001 for HCC with cirrhosis vs
CHB; respectively ), and A1762T/G1764A mutations (OR=1.914, 95%CI=1.188-3.085, P=0.005 for LC vs CHB;
OR=2.996, 95%CI=1.683-5.353, P=0.002 for HCC with cirrhosis vs CHB; respectively), but no differences in the frequencies
of both variants between LC and HCC with cirrhosis groups were found.
Conclusions: HBV subgenotype C2 infection and A1762T/G1764A mutations are both risk factors of LC and HCC
with cirrhosis development in the patients with CHB in Southeast China, but all no helpful for predicting HCC development
in LC patients
Keywords :
Hepatitis B Virus , Basal core promoter , Liver cirrhosis , Hepatocellular carcinoma
